Piramal Pharma Limited’s Pharma Solutions (PPS) business, a leading Contract Development and Manufacturing Organization (CDMO), today formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. This new expansion significantly adds primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
With this expansion, Piramal Pharma Solutions is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a wide range of in-vitro screening technology tools to support its broad portfolio of research services. The goal is to generate data that provides a superior data package for clients and enhance the company’s value as an outsourcing partner. The benefits of this new investment will be seen in an improved experience for PPS discovery services customers. The integration of chemistry and biology services under one roof promises to add high efficiency to the discovery process. To enable this expansion, PPS is committed to bringing in experienced personnel with a demonstrated track record in biology services, complementing the existing technical and operational expertise.
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “Through these enhanced in-vitro biology services, our drug discovery team will be able to provide clients with decision-driving information earlier and will be an even more effective partner in the drug discovery process.”
The new high-throughput screening format enables PPS to evaluate and screen large collections using various assay platform technologies including, but not limited to, TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) / HTRF (Homogeneous Time-Resolved Fluorescence), Fluorescence Polarization (FP), absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, flow cytometry and high-content imaging. These platforms will be applicable to a variety of targets including but not limited to G-Protein-Coupled Receptors (GPCRs) and kinases.